A compound targeting APOL2 and its uses
By combining small molecule compounds targeting APOL2 with immune checkpoint blockade therapy and oncolytic virus therapy, the non-selective killing and drug resistance problems of existing tumor treatment methods have been solved, achieving highly effective treatment for a variety of cancers.
Patent Information
- Application Number
- CN202610666613.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2026-05-14
- Publication Date
- 2026-11-17
AI Technical Summary
Existing cancer treatments suffer from serious toxic side effects and drug resistance due to non-selective killing, while target mutations in targeted therapy limit long-term efficacy. There is an urgent need to discover novel tumor-specific targets, especially key molecules that regulate tumor cell survival, metabolism, or immune escape.
Develop small molecule compounds that target APOL2, regulate its expression and activity by targeting and binding to APOL2, and combine them with immune checkpoint blockade therapy and oncolytic virus therapy to achieve targeted killing of tumor cells.
It improves the specificity and effectiveness of tumor treatment, reduces toxic side effects, prolongs the survival of cancer patients, and is applicable to the treatment of a variety of cancers.
Smart Images

Figure CN123106501A_ABST
Abstract
Description
[0001] This application claims priority to an earlier application filed on May 16, 2025, with the China National Intellectual Property Administration, patent application number 2025106331580, entitled "A Targeting APOL2 Compound and Its Use Thereof". The entire contents of the earlier application are incorporated herein by reference. Technical Field
[0002] This invention belongs to the pharmaceutical field, specifically relating to a small molecule compound that targets APOL2 and its uses. Background Technology
[0003] Currently, cancer treatment mainly relies on chemotherapy, radiotherapy, and targeted therapy. However, traditional therapies cause serious toxic side effects (such as bone marrow suppression and organ damage) due to non-selective killing, and drug resistance is becoming increasingly prominent. Although targeted therapy significantly improves specificity (such as EGFR and HER2 inhibitors), drug resistance mechanisms caused by target mutations (such as the T790M mutation) limit long-term efficacy. Therefore, there is an urgent need to discover novel tumor-specific targets, especially key molecules that regulate tumor cell survival, metabolism, or immune escape.
[0004] Apolipoprotein L2 (APOL2) belongs to the apolipoprotein family, whose proteins are involved in lipid metabolism and cell membrane stability. Recent studies have revealed aberrant expression of APOL2 in tumors; elevated APOL2 expression in melanoma, breast cancer, colorectal cancer, bladder cancer, ovarian cancer, endometrial cancer, thyroid cancer, and malignant neurotumors is significantly positively correlated with patient prognosis and survival. Currently, no small-molecule antitumor drugs targeting APOL2 have been reported; therefore, developing such drugs has significant clinical therapeutic implications. Summary of the Invention
[0005] The first aspect of this invention provides a compound of Formula I, or a stereoisomer thereof, or a deuterated compound thereof, or a pharmaceutically acceptable salt thereof:
[0006] Formula I; In formula I, Ar1 and Ar2 are each independently selected from 4-7 cyclic aromatic rings and 4-7 heterocyclic aromatic rings; R 1 R 2 Each group is independently selected from hydrogen, halogen, cyano, nitro, and -C. 0~4 Alkylene-OR 12 -C 0~4 Alkylene-OC(O)R 12 -C 0~4Alkylene-SR 12 -C 0~4 Alkylene-S(O)2R 12 -C 0~4 Alkylene-S(O)R 12 -C 0~4 Alkylene-S(O)2NR 12 R 13 -C 0~4 Alkylene-S(O)NR 12 R 13 -C 0~4 Alkylene-C(O)R 12 -C 0~4 Alkylene-C(O)OR 12 -C 0~4 Alkylene-C(O)NR 12 R 13 -C 0~4 Alkylene-NR 12 R 13 -C 0~4 Alkylene-NR 12 C(O)R 13 -C 0~4 Alkylene-NR 12 S(O)2R 13 -C 0~4 Alkylene-NR 12 S(O)R 13 -C 0~4 Alkylene (3- to 10-membered cycloalkyl), -C 0~4 Alkylene (3- to 10-membered heterocyclic alkyl), -C 0~4 alkylene-(6-10 membered aromatic ring), -C 0~4 Alkylene rings (5-10 membered heteroaryl rings); R 12 R 13 Selected independently from hydrogen and -C 0~4 Alkylene (3- to 10-membered cycloalkyl), -C 0~4 Alkylene (3- to 10-membered heterocyclic alkyl), -C 0~4 alkylene-(6-10 membered aromatic ring), -C 0~4 alkylene-(5-10 membered heteroaryl ring), -C 0~4 Alkylene-C(O)R 14 ; wherein, the alkylene group, cycloalkyl group, heterocycloalkyl group, aromatic ring, heteroaromatic ring, amide group, and carbonyl group may be optionally replaced by one, two, three, or four independent R groups. 14 replace; The R 14 Selected from hydrogen, halogen, cyano, nitro, -C 1~6alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group, -C 0~4 Alkylene (3- to 10-membered cycloalkyl), -C 0~4 Alkylene (3- to 10-membered heterocyclic alkyl), -C 0~4 alkylene-(6-10 membered aromatic ring), -C 0~4 Alkylene rings (5-10 membered heteroaryl rings); In a specific embodiment of the present invention, Ar1 and Ar2 are each independently selected from 5-6 membered aromatic rings and 5-6 membered aromatic heterocycles; more preferably, they are 6 membered aromatic rings, 5 membered aromatic heterocycles, or 5 membered aromatic heterocycles. In a specific embodiment of the present invention, the R 1 R 2 Each is independently selected from hydrogen, -C 0~4 Alkylene-OR 12 -C 0~4 Alkylene-C(O)NR 12 R 13 ; In a specific embodiment of the present invention, the R 12 R 13 Selected independently from hydrogen and -C 0~4 Alkylene (3- to 10-membered heterocyclic alkyl), -C 0~4 alkylene-(6-10 membered aromatic ring), -C 0~4 Alkylene-C(O)R 14 ; In a specific embodiment of the present invention, the R 14 Selected from hydrogen, -C 1~6 alkyl, -C 0~4 alkylene-(6-10 membered aromatic ring), -C 0~4 Alkylene (3- to 10-membered heterocyclic alkyl); In a specific embodiment of the present invention, the alkylene group, cycloalkyl group, heterocycloalkyl group, aromatic ring, heteroaromatic ring, amide group, and carbonyl group may be optionally replaced by one, two, three, or four independent R groups. 14 replace; In a specific embodiment of the present invention, Ar1 and Ar2 are each independently selected from a benzene ring, a pyridine ring, and an imidazole ring; In a specific embodiment of the present invention, Ar1 is selected from benzene rings and imidazole rings; In a specific embodiment of the present invention, Ar2 is selected from benzene rings and pyridine rings; In a specific embodiment of the present invention, the R 1 Selected from -OR 12 -C(O)NR 12 R 13 ; In a specific embodiment of the present invention, the R 2 Selected from hydrogen, -OR 12 ; In a specific embodiment of the present invention, R 12 R 13 Selected independently from hydrogen, ; In a specific embodiment of the present invention, the R 14 Selected from hydrogen, methyl, ; In a specific embodiment of the present invention, Ar1 and Ar2 are benzene rings; In a specific embodiment of the present invention, Ar1 is an imidazole ring and Ar2 is a pyridine ring; In a specific embodiment of the present invention, R1 is a phenoxy group; In a specific embodiment of the present invention, R1 is ; In a specific embodiment of the present invention, R2 is hydrogen; In a specific embodiment of the present invention, R2 is ; In a specific embodiment of the present invention, the compound of formula I is specifically:
[0007] TM-1,
[0008] TM-2.
[0009] In a specific embodiment of the present invention, the compound of formula I has the structure shown in formula II:
[0010] Formula II in, Ar2 is selected from benzene ring and pyridine ring; R 1 Selected from -OR 12 ; R 12 Independently selected from -C 0~4 Alkylene (3- to 10-membered cycloalkyl), -C 0~4Alkylene (6-10 membered aromatic rings); R 3 Selected from -C 0~4 Alkylene-C(O)OR 5 -C 0~4 Alkylene-C(O)NR 5 R 6 ; R 4 Selected from -C 0~4 Alkylene-C(O)OR 5 -C 0~4 Alkylene-C(O)NR 5 R 6 ; R 5 R 6 Selected independently from hydrogen and -C 1~6 alkyl, -C 3~6 cycloalkyl groups.
[0011] Preferably, Ar2 is selected from 1,4-benzene ring or 1,3-benzene ring.
[0012] This invention provides a method for preparing a compound of formula (II), or a stereoisomer thereof, or a deuterated compound thereof, or a pharmaceutically acceptable salt thereof, wherein the method comprises: Compound A-3 is obtained by coupling reaction of compound A-1 and compound A-2. Compound A-3 is then deprotected to obtain compound A-4. Compound A-4 and compound A-5 are then condensed to obtain compound (II), wherein G is a halogen and T is an amino protecting group.
[0013] In a specific embodiment of the present invention, the compound of formula I has the structure shown in formula III:
[0014] Formula III in, Ar2 is selected from benzene ring and pyridine ring; R 7 Selected from -C0~4 alkylene- (6~10-membered aromatic rings), wherein the 6~10-membered aromatic ring is unsubstituted or C-substituted. 1~6 Alkyl substitution; R 8 Selected from -NR 12 C(O)R 13 ; R 12 R 13 Selected independently from hydrogen and -C 1~6 alkyl, -C 3~6cycloalkyl groups.
[0015] Preferably, Ar2 is selected from 1,4-phenylene, 1,3-phenylene, , , , .
[0016] This invention provides a method for preparing a compound of formula (III), or a stereoisomer thereof, or a deuterated compound thereof, or a pharmaceutically acceptable salt thereof, wherein the method comprises: Compound B-1 was acylated to give compound B-2, and compound B-2 was deprotected to give compound B-3. Compound B-3 was further acylated with compound B-4 to give compound B-5, and compound B-5 was deprotected to give compound B-6. Compound B-6 and compound B-7 were then acylated to give compound (III), where T is an amino protecting group.
[0017] In a second aspect, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of at least one of the compounds represented by Formula I, or a stereoisomer thereof, or a deuterated compound thereof, or a pharmaceutically acceptable salt thereof.
[0018] According to embodiments of the present invention, the pharmaceutical composition further includes one, two, or more pharmaceutically acceptable excipients.
[0019] According to an embodiment of the invention, the pharmaceutical composition further comprises one or more additional therapeutic agents.
[0020] According to embodiments of the present invention, the pharmaceutical composition further comprises one or more additional drugs for treating or preventing cancer.
[0021] According to the present invention, the pharmaceutical compositions of the present invention can be formulated into dosage forms suitable for administration by methods known in the art.
[0022] The third aspect of the present invention provides the use of the compound described in the first aspect above, or its stereoisomer, or its deuterated compound, or its pharmaceutically acceptable salt, or the pharmaceutical composition described in the second aspect above, in the preparation of a medicament for treating diseases related to abnormal cell proliferation.
[0023] In this invention, the disease is a tumor-related disease; The present invention also provides the use of any of the compounds described above in any aspect, or stereoisomers thereof, or deuterated compounds thereof, or pharmaceutically acceptable salts thereof, or the pharmaceutical compositions described in the second aspect above, in the preparation of a medicament for treating tumors.
[0024] In another aspect of the invention, the invention provides the use of the compound of Formula I described above, or a stereoisomer thereof, or a deuterated compound thereof, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition described in the second aspect above, in the preparation of a medicament for treating cancer in an individual or delaying the progression of cancer in an individual; Furthermore, the drug is a drug that targets APOL2; In a specific embodiment of the present invention, the tumor is selected from liver cancer, breast cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer, medulloblastoma, melanoma, non-small cell lung cancer, small cell lung cancer, cervical cancer, ovarian cancer, bladder cancer, thyroid cancer, head and neck cancer, prostate cancer, fibroblastoma, leukemia, myeloma, and lymphoma.
[0025] A fourth aspect of the present invention provides a method for promoting tumor cell death, comprising using drug molecules to target and activate APOL2 expression and / or activity, regulating the APOL2 pathway, and causing tumor cells expressing APOL2 to die; In this invention, the drug molecule is a chemical drug or a biological drug; Furthermore, the chemical drug is as defined in Formula I above; Furthermore, the chemical drug is defined as described in the definition of the compound in the first aspect above or the pharmaceutical composition in the second aspect above; In one aspect of the invention, the invention provides a method for reducing tumor size or inhibiting tumor growth in a tumor subject in need, comprising administering an effective amount of the compound of formula I described above to the subject; wherein the compound of formula I targets and binds to APOL2; Furthermore, the terms in the compound of formula I are defined as described in the first aspect above; Furthermore, in this invention, the above-described method may further include administering immune checkpoint blockade therapy and / or oncolytic virus therapy to the subject in combination; Furthermore, the immune checkpoint blockade therapy is the administration of an immune checkpoint inhibitor; In a specific embodiment of the present invention, the immune checkpoints may include, but are not limited to, PD-1 and / or CTLA4; In a fifth aspect, the present invention provides a combined antitumor treatment method, wherein the combined antitumor treatment method is a combination of targeted binding to APOL2 with immune checkpoint blockade therapy, adoptive immune cell therapy, and / or oncolytic virus therapy, and is administered to tumor subjects in need. In a specific embodiment of the present invention, the tumor is a solid tumor or a non-solid tumor; In this invention, the above-described method administers the compound of Formula I by oral administration or by intradermal, subcutaneous, intraperitoneal, intratumoral, intramuscular, intravenous, arterial, intrathecal injection or intracavitary administration or a combination thereof. In this invention, the application of the compound of formula I includes direct application or application of a composition containing the compound of formula I; wherein the composition further comprises pharmaceutically acceptable excipients; In this invention, "pharmaceuticalally acceptable excipients" include any solvent, dispersion medium, coating material, surfactant, antioxidant, preservative (e.g., antibacterial, antifungal), isotonic agent, salt, pharmaceutical stabilizer, binder, excipient, dispersant, lubricant, sweetener, flavoring agent, colorant, or combinations thereof, all of which are known to those skilled in the art (as described in Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329). The use of these carriers in therapeutic or pharmaceutical compositions is covered, except in cases where any conventional carrier is incompatible with the active ingredient.
[0026] The effective dosage described in this invention can vary depending on the administration method and the severity of the disease to be treated. A preferred effective dosage can be determined by those skilled in the art based on various factors (e.g., through clinical trials). These factors include, but are not limited to: pharmacokinetic parameters of the bioactive ingredient, such as bioavailability, metabolism, and half-life; the severity of the disease to be treated, the patient's weight, the patient's immune status, and the route of administration. For example, due to the urgency of the treatment, several separate doses may be administered daily, or the dose may be reduced proportionally.
[0027] The compositions of the present invention can be incorporated into medicaments suitable for parenteral administration (e.g., intradermal, subcutaneous, intraperitoneal, intratumoral, intramuscular, intravenous, arterial, intrathecal, intracavitary). These medicaments can be prepared in various forms, such as liquids, semi-solids, and solid dosage forms, including but not limited to liquid solutions (e.g., injectable solutions and infusion solutions) or lyophilized powders.
[0028] The compounds or compositions of the present invention are administered using typical pharmaceutical routes, such as oral solid dosage forms and injectable liquid dosage forms. The compounds or compositions of the present invention can be administered orally, intravenously, by injection, intramuscularly, or subcutaneously, specifically by oral administration or intradermal, subcutaneous, intraperitoneal, intratumoral, intramuscular, intravenous, arterial, intrathecal, or intracavitary administration, or a combination thereof.
[0029] The compounds and derivatives provided in this invention can be named according to the IUPAC (International Union of Pure and Applied Chemistry) or CAS (Chemical Abstracts Service, Columbus, OH) nomenclature systems.
[0030] Regarding the definition of terms used in this invention: Unless otherwise stated, the initial definitions provided for groups or terms herein apply to the groups or terms used throughout this specification; for terms not specifically defined herein, the meanings that a person skilled in the art would give them should be given based on the disclosure and context.
[0031] "Substitution" refers to the replacement of hydrogen atoms in a molecule by other different atoms or molecules. "Substitution" can also refer to the replacement of lone pairs of electrons in atoms in a molecule by "=O", "=S", etc.
[0032] "Can be further replaced" means that "replacement" can but does not have to happen, and this statement includes situations where it may or may not happen.
[0033] The minimum and maximum carbon atom content in hydrocarbon groups are indicated by a prefix, for example, the prefix C. a~b Alkyl indicates any alkyl group containing "a" to "b" carbon atoms. Therefore, for example, "C 1~4 "Alkyl" refers to an alkyl group containing 1 to 4 carbon atoms.
[0034] "Alkyl" refers to a saturated hydrocarbon chain having a specified number of member atoms. For example, C1-6 alkyl refers to an alkyl group having 1 to 6 member atoms, such as 1 to 4 member atoms. Alkyl groups can be straight-chain or branched. Representative branched alkyl groups have one, two, or three branches. Alkyl groups may optionally be substituted by one or more substituents as defined herein. Alkyl groups include methyl, ethyl, propyl (n-propyl and isopropyl), butyl (n-butyl, isobutyl, and tert-butyl), pentyl (n-pentyl, isopentyl, and neopentyl), and hexyl. Alkyl groups may also be part of other groups, such as C1-6 alkoxy groups.
[0035] In this invention, "alkylene" refers to a divalent saturated aliphatic hydrocarbon group having a specified number of carbon atoms. "C" a ~ b "Alkylene" refers to an alkylene group having a to b carbon atoms. Alkylene groups include branched and straight-chain hydrocarbon groups. For example, "C 1~6 "alkylene" is intended to include methylene, ethylene, propylene, 2-methylpropylene, dimethylethylene, pentylene, etc. Furthermore, the term "(C1-6)alkylene" is intended to include such branched hydrocarbon groups, such as cyclopropylmethylene, which can be exemplified by the following structures: For example, -C0~4 alkylene groups can be C0 alkylene, C1 alkylene (e.g., -CH2-), C2 alkylene (e.g., -CH2CH2-), C3 alkylene, or C4 alkylene; C0 alkylene refers to the absence of a group here, which is connected by a chemical bond. For example, A-C0 alkylene-B refers to AB, that is, the A group and the B group are directly connected by a chemical bond.
[0036] "Alkenyl" refers to a straight-chain or branched hydrocarbon group having a specified number of carbon atoms and, in some embodiments, 2 to 6 carbon atoms or 2 to 4 carbon atoms and having at least one vinyl unsaturated site (>C=C<). For example, C a-b Alkenyl refers to an alkenyl group having a to b carbon atoms and is intended to include, for example, vinyl, propenyl, isopropenyl, 1,3-butadienyl, etc.
[0037] In this invention, "alkenyl" refers to a hydrocarbon chain having 2 to 10 carbon atoms, at least one double bond, and two unsaturated valences. For example, (C3-C6) alkenyl groups include >C=CH-CH2-, -CH-CH=CH-CH2-, etc.
[0038] "Alynyl" refers to a straight-chain monovalent hydrocarbon group or a branched monovalent hydrocarbon group containing at least one triple bond. The term "alkynyl" is also intended to include hydrocarbon groups having one triple bond and one double bond. For example, (C2-C6) alkynyl is intended to include ethynyl, propynyl, etc.
[0039] "Halogen" refers to fluorine, chlorine, bromine, or iodine.
[0040] "Halogenated alkyl" or "halogen-substituted alkyl" refers to an alkyl group in which one or more hydrogen atoms can be replaced by one or more halogen atoms. For example, C 1~4 Halogenated alkyl refers to an alkyl group containing 1 to 4 carbon atoms in which one or more hydrogen atoms are replaced by one or more halogen atoms.
[0041] In this invention, “-OR*”, “-NR*R**”, etc., refer to R* or R** groups that are connected to oxygen or nitrogen atoms by a single bond.
[0042] In this invention, the oxygen atom in “-C(O)R*”, “-S(O)2R*”, etc., is connected to the carbon atom or sulfur atom by a double bond, and the R group is connected to the oxygen atom or sulfur atom by a single bond.
[0043] In this invention, "cycloalkyl" refers to a saturated or partially saturated cyclic group having multiple carbon atoms and no heterocyclic atoms, and having a single ring or multiple rings (including fused, bridged, spirocyclic, and adamantane systems). For polycyclic systems having aromatic and non-aromatic rings without heteroatoms, the term "cycloalkyl" (e.g., 5, 6, 7, 8,-tetrahydronaphthalene-5-yl) applies when the connecting point is located on a non-aromatic carbon atom. The term "cycloalkyl" includes cycloalkenyl groups, such as cyclohexenyl. Examples of cycloalkyl groups include, for example, adamantyl, cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclooctyl, cyclopentenyl, and cyclohexenyl. Examples of cycloalkyl groups including polycyclic dicycloalkyl ring systems are dicyclohexyl, dicyclopentyl, dicyclooctyl, etc. , , Adamantyl groups include, but are not limited to, the following structures: .
[0044] In this invention, "heterocyclic" and "heterocyclic alkyl" refer to a saturated ring or a non-aromatic unsaturated ring containing at least one heteroatom; where the heteroatom refers to nitrogen, oxygen, sulfur, etc. Generally, it represents a monovalent saturated or partially unsaturated monocyclic or bicyclic ring system with multiple ring atoms, preferably a monovalent saturated or partially unsaturated monocyclic or bicyclic ring system with 3 to 9 ring atoms, containing 1, 2, or 3 cyclic heteroatoms selected from N, O, and S, with the remaining ring atoms being carbon. A bicyclic ring refers to a ring consisting of two rings sharing two ring atoms, i.e., the bridge separating the two rings is a single bond or a chain of one or two ring atoms. Examples of monocyclic saturated heterocyclic alkyl groups are oxobutyl, aziridine, pyrrolidinyl, 2-oxo-pyrrolidin-3-yl, tetrahydrofuranyl, tetrahydro-thiophenyl, pyrazolyl, imidazoalkyl, thiazoalkyl, piperidinyl, tetrahydropyranyl, tetrahydrothiaranyl, piperazine, morpholinyl, etc. Thiomorpholinyl, 1,1-dioxo-thiomorpholin-4-yl, azirmonyl, diazarmonyl, periperazinyl, or oxazarmonyl. Examples of bicyclic saturated heterocyclic alkyl groups are 8-aza-bicyclo[3.2.1]octyl, quininecycloyl, 8-oxa-3-aza-bicyclo[3.2.1]octyl, 9-aza-bicyclo[3.3.1]nonyl, Examples of partially unsaturated heterocyclic alkyl groups are dihydrofuranyl, imidazolinyl, tetrahydropyridyl, or dihydropyranyl.
[0045] In this invention, "aromatic ring" and "aryl" refer to aromatic hydrocarbon groups having multiple carbon atoms. Aryl groups are typically monocyclic, bicyclic, or tricyclic aryl groups having 5-20 carbon atoms. Furthermore, the term "aryl" as used herein refers to an aromatic substituent that can be a single aromatic ring or multiple aromatic rings fused together. Non-limiting examples include phenyl, naphthyl, or tetrahydronaphthyl.
[0046] In this invention, "aromatic heterocycle" refers to an aromatic unsaturated ring containing at least one heteroatom; wherein the heteroatom refers to a nitrogen atom, an oxygen atom, or a sulfur atom. Typically, it refers to an aromatic monocyclic or bicyclic hydrocarbon containing multiple ring atoms, one or more of which are selected from O, N, and S heteroatoms. Preferably, it has one to three heteroatoms. Examples of heterocyclic aryl groups include: pyridyl, indolyl, quinoxalinyl, quinolinyl, isoquinolinyl, benzothiopheneyl, benzofuranyl, benzothiopheneyl, benzopyranyl, benzothiapyranyl, furanyl, pyrroleyl, thiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazoleyl, thiopheneyl, oxadiazolyl, benzimidazoleyl, benzothiazolyl, and benzoxazolyl.
[0047] "Stereoisomers" include enantiomers and diastereomers; The "deuterated compound" of this invention refers to a molecule or group in which one or more hydrogen atoms are replaced by deuterium atoms, wherein the proportion of deuterium atoms is greater than the abundance of deuterium in nature.
[0048] The term "pharmaceutically acceptable" means that a carrier, delivery substance, diluent, excipient, and / or the salt formed therefrom is generally chemically or physically compatible with other components constituting a drug dosage form and physiologically compatible with receptors.
[0049] The terms "salt" and "pharmaceutically acceptable salt" refer to acidic and / or basic salts formed by the above-described compounds or their stereoisomers with inorganic and / or organic acids and bases, including zwitterionic salts (internal salts) and quaternary ammonium salts, such as alkylammonium salts. These salts can be obtained directly during the final separation and purification of the compounds. Alternatively, they can be obtained by mixing the above-described compounds, or their stereoisomers, with an appropriate (e.g., equimolar) amount of acid or base. These salts may be obtained by precipitating in solution and collecting by filtration, or by recovery after solvent evaporation, or by freeze-drying after reaction in an aqueous medium. The salts described in this invention can be hydrochlorides, sulfates, citrates, benzenesulfonates, hydrobromides, hydrofluoric acids, phosphates, acetates, propionates, succinates, oxalates, malates, succinates, fumarates, maleates, tartrates, or trifluoroacetates of the compounds.
[0050] Obviously, based on the above description of the present invention, and according to common technical knowledge and conventional methods in the field, various other modifications, substitutions or alterations can be made without departing from the basic technical concept of the present invention. Attached Figure Description
[0051] Figure 1 The bar chart shows the cytotoxicity assay of the TM-1 compound in Experiment Example 4. Figure 2 This is a bar chart showing the cytotoxicity of the TM-2 compound in Experiment Example 4. Detailed Implementation
[0052] The following detailed embodiments further illustrate the above-described content of the present invention. However, this should not be construed as limiting the scope of the present invention to the following examples. All technologies implemented based on the above-described content of the present invention fall within the scope of the present invention.
[0053] It should be noted that, regarding the technical solutions disclosed in the embodiments or implementation schemes of this invention, this invention intends to cover all alternative, modified, and equivalent technical solutions, all of which are included within the scope of this invention. Those skilled in the art should recognize that many similar or equivalent methods and materials can be used to practice this invention. This invention is by no means limited to the methods and materials described herein. In the event that one or more of the cited documents, patents, and similar materials differ from or contradict this application (including but not limited to defined terminology, terminology application, described techniques, etc.), this invention shall prevail.
[0054] It should be further appreciated that certain features of the invention, for clarity, have been described in multiple independent embodiments or implementations, but may also be provided in combination in a single embodiment or implementation. Conversely, various features of the invention, for brevity, have been described in a single embodiment or implementation, but may also be provided individually or in any suitable sub-combination.
[0055] Definitions and explanations: Unless otherwise indicated, the technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains, and unless otherwise indicated, all patent publications cited in the entirety of this disclosure are incorporated herein by reference.
[0056] In this document, the terms “comprising” or “including” are open-ended expressions, meaning that they include the contents specified in this invention, but do not exclude other aspects.
[0057] In this document, the terms “optionally,” “optionally,” or “optionally” generally refer to an event or condition that may, but may not, occur, and the description includes both cases in which the event or condition occurs and cases in which the event or condition does not occur.
[0058] In this document, the term "pharmaceutically acceptable" means that a substance or composition must be chemically and / or toxicologically compatible with other components of the formulation and / or the mammals to which it is treated.
[0059] In this document, the term "one or more" (e.g., in the definition of substituents in compounds of the general formula of the present invention) means "one, two, three, four or five, especially one, two, three or four, more especially one, two or three, and even more especially one or two".
[0060] In this document, the term "treatment" refers to the administration of a drug or compound to an individual to achieve a desired pharmacological and / or physiological effect. This effect may be preventative in terms of complete or partial prevention of a disease or its symptoms, and / or therapeutic in terms of partial or complete cure of a disease and / or adverse effects caused by the disease. As used herein, "treatment" encompasses diseases in mammals, particularly humans, including: (a) prevention of disease or the onset of a condition in an individual who is susceptible but has not yet been diagnosed with the disease; (b) inhibition of disease, such as blocking disease progression; or (c) relief of disease, such as reducing symptoms associated with the disease. As used herein, "treatment" encompasses any administration of a drug or compound to an individual to treat, cure, relieve, improve, reduce, or inhibit the individual's disease, including but not limited to administration of a drug containing a compound described herein to an individual in need.
[0061] The effective dosage described in this invention can vary depending on the administration method and the severity of the disease to be treated. A preferred effective dosage can be determined by those skilled in the art based on various factors (e.g., through clinical trials). These factors include, but are not limited to: pharmacokinetic parameters of the bioactive ingredient, such as bioavailability, metabolism, and half-life; the severity of the disease to be treated, the patient's weight, the patient's immune status, and the route of administration. For example, due to the urgency of the treatment, several separate doses may be administered daily, or the dose may be reduced proportionally.
[0062] The known starting materials of this invention can be synthesized using or according to methods known in the art, or can be purchased from companies such as Anaiji Chemical, Chengdu Kelong Chemical, Shaoyuan Chemical Technology, and Bailingwei Technology.
[0063] Unless otherwise specified in the examples, the reaction temperature is room temperature. Room temperature is the optimal reaction temperature, which is 20°C to 30°C. Unless otherwise specified in the examples, M represents moles per liter.
[0064] The structure of the compound was determined by nuclear magnetic resonance (NMR) and mass spectrometry (MS). NMR shifts (δ) are given in units of 10⁻⁶ (ppm). NMR measurements were performed using a Bruker Avance III 400 and a Bruker Avance 600 NMR spectrometer, with deuterated dimethyl sulfoxide (DMSO) as the solvent. d 6 ), deuterated chloroform (CDCl3), deuterated methanol (Methol- d4 The internal standard was tetramethylsilane (TMS). LC-MS was performed using a Shimadzu LC-MS 2020 (ESI) system. HPLC was performed using a Shimadzu LC-20A high-performance liquid chromatograph. MPLC (medium-pressure preparative chromatography) was performed using a Gilson GX-281 reversed-phase preparative chromatograph. Thin-layer chromatography used Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plates, with a thickness of 0.4 mm to 0.5 mm for product separation and purification. Column chromatography generally used Yantai Huanghai 200-300 mesh silica gel as the carrier.
[0065] The following are examples of specific compounds, used to represent the preparation of compounds of Formula I of the present invention, and are not intended to be the only limitation on the synthesis of compounds of Formula I; Example 1: Synthesis of TM-1 Synthesis route:
[0066] Synthesis operation: Step 1: Synthesis of Intermediate 2 A clean, 25 mL orb-shaped flask was used as the reaction vessel. Starting material 1 (500 mg, 1.15 mmol) and methylamine hydrochloride (77.6 mg, 1.15 mmol) were dissolved in N,N',N'-dimethylformamide (5 mL), followed by the addition of N,N',N'-methylimidazolium (212.5 mg, 2.53 mmol). The reagent N,N',N'-tetramethylchloroformamidine hexafluorophosphate (354.2 mg, 1.265 mmol) was added to the system at 0 °C, and the reaction mixture was stirred at 0 °C for approximately 2 hours. The reaction was quenched with 1.0 mL of water. Purification yielded a white intermediate 2 (99.04% yield). LCMS [M+H]+ m / z: 436.1.
[0067] Step 2: Synthesis of Intermediate 4 Take a 50 mL dry three-necked flask as the reaction vessel, add a magnetic stir bar, and install a thermometer on one of the three necks, a reflux tube on the other, and a three-way valve with a nitrogen balloon on the last neck. Commercial reagent intermediate 3 (English name: (4-phenoxyphenyl)boronic acid (238.16 mg, 1.11 mmol) and intermediate 2 (500 mg, 1.11 mmol) were added together to a flask, followed by anhydrous potassium carbonate (183.82 mg, 1.33 mmol). 20 mL of 1,4-dioxane and 5 mL of tap water were added directly. The system was then depressurized using a water pump and purged with a nitrogen balloon. This operation was repeated three times to maintain an inert atmosphere. Then, the catalyst Pd(dppf)Cl2 (40.2 mg, 0.055 mmol) was added under an inert atmosphere using a flexible feeder. The reaction mixture was heated to 100°C and reacted for 16 hours. After the time was up, the flask was opened, and samples were taken for analysis and detection using LCMS. After successful reaction, 15 mL of tap water was added to the system, followed by 15 mL of ethyl acetate. The extract was mixed twice with mL of solution. The mixture was washed and dried to remove the organic solvent, yielding a pale yellow crude product. Column chromatography purification gave a pale yellow intermediate 4 (56.73% yield). LCMS [M+H]+ m / z: 539.2 Step 3: Synthesis of Intermediate 5 Intermediate 4 (100 mg, 185.66 μmol, 1 equivalent) was dissolved in dichloromethane (10 mL), and trifluoroacetic acid (5 mL) was added with stirring. The mixture was stirred at room temperature for 30 min, and the reaction was monitored by LC-MS. After the reaction was complete, the solution was evaporated to dryness to obtain intermediate 5 (80 mg, crude product). LCMS [M+H]+ m / z: 439.2.
[0068] Step 4: Synthesis of the final product TM-1 Commercial intermediates 6 (29.95 mg, 182.43 μmol) and 5 (80 mg, approximately 182.43 μmol) were added sequentially to a 50 mL eggplant-shaped reaction flask equipped with a stirrer, followed by 5 mL of methanol and 0.5 mL of glacial acetic acid. The mixture was stirred at 20 °C for 0.5 h. Then, the reagent pyridine-borane complex (42.4 mg, 456.07 μmol) was added to the system at room temperature. The reaction was then stirred at room temperature for 16 h. The reaction was quenched with water and purified to obtain a yellow solid TM-1 (46.06% yield, 99.8% purity).
[0069] LCMS [M+H]+ m / z: 587.3.
[0070] 1 H NMR (600 MHz, Methanol- d 4) δ 8.05 (d, J = 8.1 Hz, 2H), 7.90 (d, J = 9.0Hz, 1H), 7.88 – 7.81 (m, 1H), 7.59 – 7.44 (m, 3H), 7.44 – 7.34 (m, 4H), 7.34– 7.24 (m, 3H), 7.20 – 7.13 (m, 1H), 7.13 – 7.03 (m, 4H), 4.97 (d, J = 6.2 Hz, 1H), 4.15 (d, J = 149.1 Hz, 3H), 3.91 (s, 3H), 3.37 (s, 2H), 2.80 (ddd, J = 15.3,9.9, 6.0 Hz, 1H), 2.60 (s, 3H), 2.10 (dd, J = 14.4, 6.1 Hz, 1H). Example 2: Synthesis of TM-2 Synthesis route:
[0071] Synthesis operation: Step 1: Synthesis of Intermediate 2 A clean, 25 mL oval-shaped flask was used as the reaction vessel. Starting material 1 (276 mg, 998.65 μmol) was added sequentially, followed by 5 mL of anhydrous dichloromethane. Triethylamine (292.0 mg, 2.89 mmol, 400 μL) was then added as a base. Acetic anhydride (217.8 mg, 2.13 mmol, 200 μL) was gradually added to the stirred solution at room temperature. The reaction was then carried out at room temperature for approximately 1 hour. The pH of the reaction system was adjusted to 8 with 1 M sodium hydroxide aqueous solution, and the mixture was then extracted twice with 10 mL of ethyl acetate. The combined organic phases were washed once with brine. The mixture was then dried over anhydrous sodium sulfate, filtered, and the filtrate was used to remove the organic solvent, yielding a pale yellow oily intermediate 2 (318 mg, crude product). This intermediate can be used directly for the next reaction without further processing. LCMS [M+H]+ m / z: 319.2 Step 2: Synthesis of Intermediate 3 Intermediate 2 (318 mg, approximately 998.71 μmol) was dissolved in dichloromethane (3 mL), and trifluoroacetic acid (2 mL) was added with stirring. The mixture was stirred at room temperature for 30 min, and the reaction was monitored by LC-MS. After the reaction was completed, the solution was evaporated to dryness to obtain a pale yellow oily crude trifluoroacetate intermediate 3 (350 mg, crude product). LCMS [M+H]+ m / z: 219.2.
[0072] Step 3: Synthesis of Intermediate 5 A clean, 25 mL orb-shaped flask was used as the reaction vessel. Commercial reagent 4 (293.0 mg, 998.78 μmol) was added to the flask, followed by crude trifluoroacetate intermediate 3 (350.0 mg, crude) and N-dimethylformamide (4 mL). Then, N-methylimidazole (1.03 g, 12.55 mmol, 1000 μL) was added. The system was stirred thoroughly until all materials were dissolved, and then cooled to 0 °C. Reagent N,N,N',N'-tetramethylchloroformamidine hexafluorophosphate (336.24 mg, 1.20 mmol) was added to the system at 0 °C, and the reaction mixture was stirred at 0 °C for approximately 2 hours. The reaction was quenched with water. The reaction solution was purified by HPLC and lyophilized to give a white solid intermediate 5 (50.0% yield). LCMS [M+H]+ m / z: 494.3.
[0073] Step 4: Synthesis of Intermediate 6 Intermediate 5 (246.6 mg, 500.0 μmol) was dissolved in dichloromethane (4 mL), and trifluoroacetic acid (2 mL) was added with stirring. The mixture was stirred at room temperature for 30 min, and the reaction was monitored by LC-MS. After the reaction was completed, the product was evaporated to dryness to obtain a pale yellow oily crude trifluoroacetate intermediate 6 (360 mg, crude product). LCMS [M+H]+ m / z: 394.3.
[0074] Step 5: Synthesis of the final product TM-2 To a 25 mL eggplant-shaped reaction flask equipped with a stirrer, crude trifluoroacetate intermediate 6 (360.0 mg, approximately 500.00 μmol) and 3 mL of DMF as solvent were added sequentially. Then, commercial reagent 7 (120 mg, 501.61 μmol) and N-methylimidazole (515.0 mg, 6.27 mmol, 500 μL) were also added sequentially. The mixture was stirred thoroughly until dissolved, and then cooled to 0 °C using an ice bath. Reagent N,N,N',N'-tetramethylchloromethylammonium hexafluorophosphate (170 mg, 605.89 μmol) was added to the system at 0 °C, and the reaction mixture was stirred at 0 °C for approximately 2 hours. The reaction was quenched with water. The mixture was extracted twice with ethyl acetate. The combined organic phases were washed once with brine. The mixture was then dried over anhydrous sodium sulfate, filtered, and the filtrate was used to remove the organic solvent, yielding a pale yellow oily crude product. The crude product was purified by HPLC and lyophilized directly to obtain the white solid final product TM-2 (48.94% yield, 97.3% purity, HPLC). LCMS [M+H]+ m / z: 615.3.
[0075] 1 H NMR (400 MHz, Methanol- d 4) δ 8.75 (ddd, J = 6.8, 4.9, 1.8 Hz, 1H),8.43 (s, 1H), 8.21 (ddd, J = 15.3, 7.7, 1.8 Hz, 1H), 7.78 – 7.71 (m, 1H), 7.66(ddd, J = 9.9, 7.7, 4.9 Hz, 1H), 7.61 – 7.38 (m, 3H), 7.37 – 7.24 (m, 2H), 7.18 – 6.99 (m, 3H), 6.99 – 6.82 (m, 2H), 4.97 (ddd, J = 11.6, 7.3, 4.4 Hz, 1H),4.41 (t, J = 11.0 Hz, 1H), 3.37 (d, J = 11.9 Hz, 1H), 3.16 (d, J = 14.4 Hz, 0H), 3.09 (dd, J= 13.4, 11.5 Hz, 1H), 2.75 – 2.61 (m, 1H), 2.54 – 2.43 (m, 1H), 2.43 – 2.22 (m, 1H), 2.16 (d, J = 4.7 Hz, 6H), 2.10 (d, J = 1.0 Hz, 3H), 1.86 –1.55 (m, 2H), 1.49 – 0.98 (m, 3H). Experiment 3: Surface Plasmon Resonance Experiment Freshly prepared recombinant hAPOL2-Strep protein was immobilized on the surface of Sensor Chip CM5 (cytiva) using an amino-coupling kit (cytiva) with a Biacore T200 instrument (cytiva). Compounds TM-1 to TM-2 prepared in Examples 1 and 2 were prepared with buffer (PBSP + 5% DMSO) at concentrations of 0.1, 0.2, 0.39, 0.78, 1.56, 3.125, 6.25, 12.5, 25, 50, and 100 μM and then contacted with the above-mentioned recombinant hAPOL2-Strep protein.
[0076] The binding affinity of hAPOL2-Strep protein to the test compounds TM-1~TM-2 was detected using a Biacore T200 instrument, and the dissociation constant K was calculated using Biacore T200 Evaluation software (Cytiva). D Dissociation constant K D Calculations were performed using Biacore T200 Evaluation Software (Version 3.1). Experimental calculations show that the dissociation constant K of TM-1 D It is 9.93×10 -5 The dissociation constant K of TM-2 D It is 7.49×10 -6 This indicates that the compounds TM-1 to TM-2 of the present invention have a strong affinity for recombinant hAPOL2-Strep protein.
[0077] Experimental Example 4: Cytotoxicity Detection Assay 5x10 3 A549 human non-small cell lung cancer cells were seeded in 96-well plates and incubated in a CO2 incubator for 24 hours for later use; stock solutions of compounds TM-1~TM-2 of this application were prepared with DMSO for later use. Test group: The prepared solutions of compounds TM-1 to TM-2 of this application were added to the 96-well plates inoculated with A549 human non-small cell lung cancer cells to working concentrations of 11 μM, 33 μM, and 100 μM, respectively. Control group (DMSO): An equal volume of DMSO was added to the 96-well plates inoculated with A549 human non-small cell lung cancer cells. Blank group: Cell-free medium containing an equal volume of DMSO was used as the blank group. Each experiment was repeated three times; cell viability in the test and control groups was detected using a CCK-8 assay kit to evaluate the toxicity of TM-1 to TM-2 of this application to A549 human non-small cell lung cancer cells. Survival rate calculation formula: Cell Viability % = (OD Test -OD Blank ) / (OD DMSO -OD Blank )×100%; The test results are as follows Figures 1-2 As shown, Figures 1-2 The images are bar charts showing the viability of compounds TM-1 to TM-2 in 549 non-small cell lung cancer cells from A1 patients. from Figures 1-2 It can be seen that the experimental groups containing compounds TM-1~TM-2 of this application showed significantly lower cell viability of A549 human non-small cell lung cancer cells compared to the DMSO control group, exhibiting strong and significant cytotoxicity. With increasing concentrations of compounds TM-1~TM-2 of this application, the cell viability of A549 human non-small cell lung cancer cells decreased significantly.
[0078] Other compounds in this application have similar beneficial effects as described above.
[0079] Other cancer cell toxicity tests of the compound of Formula I showed that it had similar effects to those described above.
Claims
1. The compound represented by Formula I, or its stereoisomer, its deuterated compound, or its pharmaceutically acceptable salt: Formula I; In formula I, Ar1 and Ar2 are each independently selected from 4-7 cyclic aromatic rings and 4-7 heterocyclic aromatic rings; R 1 R 2 Each group is independently selected from hydrogen, halogen, cyano, nitro, and -C. 0~4 Alkylene-OR 12 -C 0~4 Alkylene-OC(O)R 12 -C 0~4 Alkylene-SR 12 -C 0~4 Alkylene-S(O)2R 12 -C 0~4 Alkylene-S(O)R 12 -C 0~4 Alkylene-S(O)2NR 12 R 13 -C 0~4 Alkylene-S(O)NR 12 R 13 -C 0~4 Alkylene-C(O)R 12 -C 0~4 Alkylene-C(O)OR 12 -C 0~4 Alkylene-C(O)NR 12 R 13 -C 0~4 Alkylene-NR 12 R 13 -C 0~4 Alkylene-NR 12 C(O)R 13 -C 0~4 Alkylene-NR 12 S(O)2R 13 -C 0~4 Alkylene-NR 12 S(O)R 13 -C 0~4 Alkylene (3- to 10-membered cycloalkyl), -C 0~4 Alkylene (3- to 10-membered heterocyclic alkyl), -C 0~4 alkylene-(6-10 membered aromatic ring), -C 0~4 Alkylene rings (5-10 membered heteroaryl rings); R 12 R 13 Selected independently from hydrogen and -C 0~4 Alkylene (3- to 10-membered cycloalkyl), -C 0~4 Alkylene (3- to 10-membered heterocyclic alkyl), -C 0~4 alkylene-(6-10 membered aromatic ring), -C 0~4 alkylene-(5-10 membered heteroaryl ring), -C 0~4 Alkylene-C(O)R 14 ;in, The alkylene group, cycloalkyl group, heterocycloalkyl group, aromatic ring, heteroaromatic ring, amide group, and carbonyl group may be optionally replaced by one, two, three, or four independent R groups. 14 replace; The R 14 Selected from hydrogen, halogen, cyano, nitro, -C 1~6 alkyl, -C 2~6 alkenyl, -C 2~6 Alkyne- or halogen-substituted -C 1~6 Alkyl, halogen-substituted -C 2~6 Alkenyl, halogen-substituted -C 2~6 alkynyl group, -C 0~4 Alkylene (3- to 10-membered cycloalkyl), -C 0~4 Alkylene (3- to 10-membered heterocyclic alkyl), -C 0~4 alkylene-(6-10 membered aromatic ring), -C 0~4 Alkylene rings (5-10 membered heteroaryl rings). Preferably, Ar1 and Ar2 are each independently selected from 5-6 membered aromatic rings and 5-6 membered aromatic heterocycles. Preferably, the R 1 R 2 Each is independently selected from hydrogen, -C 0~4 Alkylene-OR 12 -C 0~4 Alkylene-C(O)NR 12 R 13 . Preferably, the R 12 R 13 Selected independently from hydrogen and -C 0~4 Alkylene (3- to 10-membered heterocyclic alkyl), -C 0~4 alkylene-(6-10 membered aromatic ring), -C 0~4 Alkylene-C(O)R 14 . Preferably, the R 14 Selected from hydrogen, -C 1~6 alkyl, -C 0~4 alkylene-(6-10 membered aromatic ring), -C 0~4 Alkylene (3- to 10-membered heterocyclic alkyl).
2. The compound according to claim 1, characterized in that: Ar1 and Ar2 are each independently selected from benzene ring, pyridine ring, and imidazole ring; or, The R 1 Selected from -OR 12 -C(O)NR 12 R 13 ; The R 2 Selected from hydrogen, -OR 12 ; or, R 12 R 13 Selected independently from hydrogen, ; or, The R 14 Selected from hydrogen, methyl, 。 3. The compound represented by Formula II, or its stereoisomer, its deuterated compound, or its pharmaceutically acceptable salt: Formula II in, Ar2 is selected from benzene ring and pyridine ring; R 1 Selected from -OR 12 ; R 12 Independently selected from -C 0~4 Alkylene (3- to 10-membered cycloalkyl), -C 0~4 Alkylene (6-10 membered aromatic rings); R 3 Selected from -C 0~4 Alkylene-C(O)OR 5 -C 0~4 Alkylene-C(O)NR 5 R 6 ; R 4 Selected from -C 0~4 Alkylene-C(O)OR 5 -C 0~4 Alkylene-C(O)NR 5 R 6 ; R 5 R 6 Selected independently from hydrogen and -C 1~6 alkyl, -C 3~6 cycloalkyl groups.
4. The compound represented by Formula III, or its stereoisomer, or its deuterated compound, or its pharmaceutically acceptable salt: Formula III in, Ar2 is selected from benzene ring and pyridine ring; R 7 Selected from -C0~4 alkylene- (6~10-membered aromatic rings), wherein the 6~10-membered aromatic ring is unsubstituted or C-substituted. 1~6 Alkyl substitution; R 8 Selected from -NR 12 C(O)R 13 ; R 12 R 13 Selected independently from hydrogen and -C 1~6 alkyl, -C 3~6 cycloalkyl groups.
5. Selected from the following compounds: TM-1, TM-2.
6. A method for preparing the compound according to claim 3 or 5, or its stereoisomer, its deuterated compound, or its pharmaceutically acceptable salt, wherein the preparation method comprises: Compound A-3 is obtained by coupling reaction of compound A-1 and compound A-2. Compound A-3 is then deprotected to obtain compound A-4. Compound A-4 and compound A-5 are then condensed to prepare compound II (such as compound TM-1), where G is a halogen and T is an amino protecting group. 。 7. A method for preparing the compound according to claim 4 or 5, or its stereoisomer, its deuterated compound, or its pharmaceutically acceptable salt, wherein the preparation method comprises: Compound B-1 is acylated to give compound B-2, which is then deprotected to give compound B-3. Compound B-3 is further acylated with compound B-4 to give compound B-5, which is then deprotected to give compound B-6. Compound B-6 is then acylated with compound B-7 to give compound III (such as compound TM-2), where T is an amino protecting group. 。 8. A pharmaceutical composition comprising a therapeutically effective amount of at least one of the compounds of any one of claims 1-5, or a stereoisomer thereof, or a deuterated compound thereof, or a pharmaceutically acceptable salt thereof.
9. Use of the compound according to any one of claims 1 to 5, or its stereoisomer, or its deuterated compound, or its pharmaceutically acceptable salt, or the pharmaceutical composition according to claim 8, in the preparation of a medicament for treating diseases related to abnormal cell proliferation. Preferably, the diseases related to abnormal cell proliferation are selected from tumors. Preferably, the tumor is a solid tumor or a non-solid tumor. Preferably, the drug is a drug that targets APOL2.
10. Use of the compound of Formula I according to any one of claims 1 to 5, or a stereoisomer thereof, or a deuterated compound thereof, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 8, in the preparation of a medicament for treating cancer in an individual or delaying the progression of cancer in an individual. Preferably, the drug is a drug that targets APOL2.
